OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Achieving clinical success with BET inhibitors as anti-cancer agents
Tatiana Shorstova, William D. Foulkes, Michael Witcher
British Journal of Cancer (2021) Vol. 124, Iss. 9, pp. 1478-1490
Open Access | Times Cited: 280
Tatiana Shorstova, William D. Foulkes, Michael Witcher
British Journal of Cancer (2021) Vol. 124, Iss. 9, pp. 1478-1490
Open Access | Times Cited: 280
Showing 1-25 of 280 citing articles:
Exploring the next generation of antibody–drug conjugates
Kyoji Tsuchikama, Yasuaki Anami, Summer Y. Y. Ha, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 3, pp. 203-223
Open Access | Times Cited: 174
Kyoji Tsuchikama, Yasuaki Anami, Summer Y. Y. Ha, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 3, pp. 203-223
Open Access | Times Cited: 174
Enhancers in disease: molecular basis and emerging treatment strategies
Annique Claringbould, Judith B. Zaugg
Trends in Molecular Medicine (2021) Vol. 27, Iss. 11, pp. 1060-1073
Open Access | Times Cited: 143
Annique Claringbould, Judith B. Zaugg
Trends in Molecular Medicine (2021) Vol. 27, Iss. 11, pp. 1060-1073
Open Access | Times Cited: 143
YAP/TAZ as master regulators in cancer: modulation, function and therapeutic approaches
Stefano Piccolo, Tito Panciera, Paolo Contessotto, et al.
Nature Cancer (2022)
Open Access | Times Cited: 142
Stefano Piccolo, Tito Panciera, Paolo Contessotto, et al.
Nature Cancer (2022)
Open Access | Times Cited: 142
Bromodomain and extraterminal (BET) proteins: biological functions, diseases and targeted therapy
Zhiqiang Wang, Zhao-Cong Zhang, Yuyang Wu, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 67
Zhiqiang Wang, Zhao-Cong Zhang, Yuyang Wu, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 67
A TCF4-dependent gene regulatory network confers resistance to immunotherapy in melanoma
Joanna Poźniak, Dennis Pedri, Ewout Landeloos, et al.
Cell (2024) Vol. 187, Iss. 1, pp. 166-183.e25
Open Access | Times Cited: 65
Joanna Poźniak, Dennis Pedri, Ewout Landeloos, et al.
Cell (2024) Vol. 187, Iss. 1, pp. 166-183.e25
Open Access | Times Cited: 65
Pharmacological targeting of the cancer epigenome
Nathaniel W. Mabe, Jennifer A. Perry, Clare F. Malone, et al.
Nature Cancer (2024) Vol. 5, Iss. 6, pp. 844-865
Closed Access | Times Cited: 19
Nathaniel W. Mabe, Jennifer A. Perry, Clare F. Malone, et al.
Nature Cancer (2024) Vol. 5, Iss. 6, pp. 844-865
Closed Access | Times Cited: 19
MYC Oncogene: A Druggable Target for Treating Cancers with Natural Products
Ka Iong Chan, Siyuan Zhang, Guodong Li, et al.
Aging and Disease (2024) Vol. 15, Iss. 2, pp. 640-640
Open Access | Times Cited: 18
Ka Iong Chan, Siyuan Zhang, Guodong Li, et al.
Aging and Disease (2024) Vol. 15, Iss. 2, pp. 640-640
Open Access | Times Cited: 18
BET bromodomain inhibitors
Martin P. Schwalm, Stefan Knapp
Current Opinion in Chemical Biology (2022) Vol. 68, pp. 102148-102148
Closed Access | Times Cited: 67
Martin P. Schwalm, Stefan Knapp
Current Opinion in Chemical Biology (2022) Vol. 68, pp. 102148-102148
Closed Access | Times Cited: 67
Small molecule photocatalysis enables drug target identification via energy transfer
Aaron Trowbridge, Ciaran P. Seath, Frances P. Rodriguez‐Rivera, et al.
Proceedings of the National Academy of Sciences (2022) Vol. 119, Iss. 34
Open Access | Times Cited: 60
Aaron Trowbridge, Ciaran P. Seath, Frances P. Rodriguez‐Rivera, et al.
Proceedings of the National Academy of Sciences (2022) Vol. 119, Iss. 34
Open Access | Times Cited: 60
Regulation of programmed cell death by Brd4
Jinfeng Hu, Dun Pan, Guo Li, et al.
Cell Death and Disease (2022) Vol. 13, Iss. 12
Open Access | Times Cited: 47
Jinfeng Hu, Dun Pan, Guo Li, et al.
Cell Death and Disease (2022) Vol. 13, Iss. 12
Open Access | Times Cited: 47
The paradigm of drug resistance in cancer: an epigenetic perspective
Swagata Adhikari, Apoorva Bhattacharya, Santanu Adhikary, et al.
Bioscience Reports (2022) Vol. 42, Iss. 4
Open Access | Times Cited: 45
Swagata Adhikari, Apoorva Bhattacharya, Santanu Adhikary, et al.
Bioscience Reports (2022) Vol. 42, Iss. 4
Open Access | Times Cited: 45
BET proteins: Biological functions and therapeutic interventions
Jiawei Guo, Qingquan Zheng, Yong Peng
Pharmacology & Therapeutics (2023) Vol. 243, pp. 108354-108354
Closed Access | Times Cited: 39
Jiawei Guo, Qingquan Zheng, Yong Peng
Pharmacology & Therapeutics (2023) Vol. 243, pp. 108354-108354
Closed Access | Times Cited: 39
BET Bromodomain Inhibitors: Novel Design Strategies and Therapeutic Applications
Kenneth K.W. To, Enming Xing, Ross C. Larue, et al.
Molecules (2023) Vol. 28, Iss. 7, pp. 3043-3043
Open Access | Times Cited: 37
Kenneth K.W. To, Enming Xing, Ross C. Larue, et al.
Molecules (2023) Vol. 28, Iss. 7, pp. 3043-3043
Open Access | Times Cited: 37
Distinct layers of BRD4-PTEFb reveal bromodomain-independent function in transcriptional regulation
Bin Zheng, Sarah Gold, Marta Iwanaszko, et al.
Molecular Cell (2023) Vol. 83, Iss. 16, pp. 2896-2910.e4
Open Access | Times Cited: 32
Bin Zheng, Sarah Gold, Marta Iwanaszko, et al.
Molecular Cell (2023) Vol. 83, Iss. 16, pp. 2896-2910.e4
Open Access | Times Cited: 32
BRD4 inhibition sensitizes diffuse large B-cell lymphoma cells to ferroptosis
Anja Schmitt, Melanie Grimm, Nina Kreienkamp, et al.
Blood (2023) Vol. 142, Iss. 13, pp. 1143-1155
Closed Access | Times Cited: 27
Anja Schmitt, Melanie Grimm, Nina Kreienkamp, et al.
Blood (2023) Vol. 142, Iss. 13, pp. 1143-1155
Closed Access | Times Cited: 27
Epigenetic Modulators as Therapeutic Agents in Cancer
Eshaan Patnaik, Chikezie O. Madu, Yi Lü
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 19, pp. 14964-14964
Open Access | Times Cited: 24
Eshaan Patnaik, Chikezie O. Madu, Yi Lü
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 19, pp. 14964-14964
Open Access | Times Cited: 24
Discovery of Novel Phenoxyaryl Pyridones as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with High Selectivity for the Second Bromodomain (BD2) to Potentially Treat Acute Myeloid Leukemia
Wenhua Jiang, Qiangqiang Hou, Hongrui Xu, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 2, pp. 1513-1532
Closed Access | Times Cited: 10
Wenhua Jiang, Qiangqiang Hou, Hongrui Xu, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 2, pp. 1513-1532
Closed Access | Times Cited: 10
Delivery of a BET protein degrader via a CEACAM6-targeted antibody–drug conjugate inhibits tumour growth in pancreatic cancer models
Youya Nakazawa, Masayuki Miyano, Shuntaro Tsukamoto, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 9
Youya Nakazawa, Masayuki Miyano, Shuntaro Tsukamoto, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 9
Current and future therapeutic strategies for high-grade gliomas leveraging the interplay between epigenetic regulators and kinase signaling networks
Lea Stitzlein, Jack T. Adams, Erin N. Stitzlein, et al.
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 8
Lea Stitzlein, Jack T. Adams, Erin N. Stitzlein, et al.
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 8
Targeted therapy, immunotherapy, and small molecules and peptidomimetics as emerging immunoregulatory agents for melanoma
Jingwen Zhang, Anthony M. Joshua, Yue Li, et al.
Cancer Letters (2024) Vol. 586, pp. 216633-216633
Open Access | Times Cited: 8
Jingwen Zhang, Anthony M. Joshua, Yue Li, et al.
Cancer Letters (2024) Vol. 586, pp. 216633-216633
Open Access | Times Cited: 8
KLF5 loss sensitizes cells to ATR inhibition and is synthetic lethal with ARID1A deficiency
Samah W. Awwad, Colm Doyle, Josie Coulthard, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 1
Samah W. Awwad, Colm Doyle, Josie Coulthard, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 1
BET Proteins as Attractive Targets for Cancer Therapeutics
Joanna Sarnik, Tomasz Popławski, Paulina Tokarz
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 20, pp. 11102-11102
Open Access | Times Cited: 53
Joanna Sarnik, Tomasz Popławski, Paulina Tokarz
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 20, pp. 11102-11102
Open Access | Times Cited: 53
Unraveling the IGF System Interactome in Sarcomas Exploits Novel Therapeutic Options
Caterina Mancarella, Andrea Morrione, Katia Scotlandi
Cells (2021) Vol. 10, Iss. 8, pp. 2075-2075
Open Access | Times Cited: 48
Caterina Mancarella, Andrea Morrione, Katia Scotlandi
Cells (2021) Vol. 10, Iss. 8, pp. 2075-2075
Open Access | Times Cited: 48
Quinazoline Based HDAC Dual Inhibitors as Potential Anti-Cancer Agents
Jyothi Dhuguru, Ola Ghoneim
Molecules (2022) Vol. 27, Iss. 7, pp. 2294-2294
Open Access | Times Cited: 34
Jyothi Dhuguru, Ola Ghoneim
Molecules (2022) Vol. 27, Iss. 7, pp. 2294-2294
Open Access | Times Cited: 34
BRD4 promotes resection and homology-directed repair of DNA double-strand breaks
John K. Barrows, Baicheng Lin, Colleen E. Quaas, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 33
John K. Barrows, Baicheng Lin, Colleen E. Quaas, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 33
